Dr Reddy’s Laboratories Ltd has announced the launch of Aspirin and extended-release Dipyridamole capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release Dipyridamole) capsules in the US market.
The Aggrenox brand and generic had US sales of approximately $182 million for the most recent 12 months ended in October, according to IMS Health.
Dr Reddy’s Aspirin and extended-release Dipyridamole capsules is available in 25 mg/200 mg strength with 60 count bottle size. Aggrenox is a trademark of Boehringer Ingelheim.